Cover Image
Market Research Report

50 Key Biopharmaceutical and Biotechnology Companies

Published by Kalorama Information Product code 594917
Published Content info 201 Pages
Delivery time: 1-2 business days
Price
Back to Top
50 Key Biopharmaceutical and Biotechnology Companies
Published: December 12, 2017 Content info: 201 Pages
Description

50 Key Biopharmaceutical and Biotechnology Companies is a comprehensive look at the top 50 companies that are shaping the biotherapeutics market in 2017 and beyond. The top 50 companies in this report were chosen for a variety of reasons, including sales of marketed biopharmaceutical products, innovation in biotherapeutics, and unique additions to the market, either marketed products or products in development.

50 Key Biopharmaceutical and Biotechnology Companies includes large traditional pharma powerhouses such as Pfizer, Novartis, Roche, Merck, GSK, Bristol-Myers Squibb, Bayer, and others; but it also includes smaller niche companies such as Genmab, Seattle Genetics, etc. In addition, it includes leading biopharmaceuticals such as Amgen and Biogen, and leading biotech companies such as Qiagen, Alexion, Agilent, Waters Co and others.

Biopharmaceuticals are therapeutic agents intended to treat symptoms and/or underlying causes of a variety of disorders and diseases. They have been a growing part of the pharmaceutical landscape since the early 1980s and is, today, one of the fastest growing areas in the pharmaceutical industry, growing at an average rate of 12%-15% over the past two years. Today, there are many biologics in the approval pipeline and it has been projected that over 65% of drugs approved for the marketplace in 2017 will be the result of biotechnology. Biopharmaceuticals hold great promise for treating some of the most intractable medical conditions such as cancer and autoimmune disease.

Biotechnology

Biotechnology is the applied knowledge of biology, it seeks to duplicate or change the function of a living cell, so it will work in a more predictable and controllable way. The biotechnology industry uses advances in genetics research to develop products for human diseases and conditions.

Biotech opportunities largely mirror those in the pharmaceutical industry. The key difference is that biotech firms are much more focused on research because they are still developing their initial products. Biotech firms tend to expand their marketing and sales forces when and if a viable product nears FDA approval.

Biopharmaceutical and Biotechnology Company Profiles:

50 Key Biopharmaceutical and Biotechnology Companies profiles these market leaders in-depth, presenting detailed information about each company, including:

  • a Corporate Summary
  • Selected Biopharmaceutical Products
  • Biopharmaceuticals in Development
  • Selected Corporate Developments
  • Company Financials
  • Regional Revenue Breakdown by Percentage (%)

Companies Profiled Include:

  • AbbVie
  • Agilent Technologies Inc.
  • Alexion Pharmaceuticals Inc
  • Allergan plc
  • Ambry Genetics
  • Amgen, Inc
  • AstraZeneca plc
  • Bayer AG
  • Berry Genomics Co Ltd.
  • Biogen
  • BioMarin Pharmaceutical Inc
  • Bristol Myers Squibb
  • Celgene
  • CRISPR Therapeutics AG
  • CSL Behring
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly & Co
  • Enzo Biochem, Inc
  • Evotec AG
  • Exelixis
  • Genmab
  • Gilead Sciences
  • GlaxoSmithKline
  • Grifols International S.A.
  • Guardant Health
  • Illumina
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co, Inc.
  • Mylan
  • Myriad Genetics
  • Novartis International AG
  • Novo Nordisk A/S
  • Organogenesis
  • Oxford Nanopore Technologies
  • Perkin Elmer, Inc
  • Pfizer
  • Precision BioSciences Inc
  • QIAGEN N.V.
  • Regeneron Pharmaceuticals
  • Roche Ltd.
  • Sanofi
  • Seattle Genetics, Inc
  • Shire
  • Takeda
  • Teva Pharmaceutical Industries, Ltd.
  • Thermo Fisher Scientific, Inc
  • UCB S.A.
  • United Therapeutics Corporation
  • Waters Corporation
Table of Contents
Product Code: KLI15550511

Table of Contents

1: EXECUTIVE SUMMARY

INTRODUCTION

SCOPE AND METHODOLOGY

MARKET SUMMARY

  • Figure 1-1: Summary: Top 10 of the Top 50 Biotechnology Companies by Biologic Revenues 2017 ($ billions)

2: INTRODUCTION

BIOPHARMACEUTICALS AND BIOTHERAPEUTICS

  • Biopharmaceuticals
  • Biotechnology
  • Areas of Treatment for Biopharmaceuticals

REGULATIONS FOR BIOPHARMACEUTICALS

3: 50 KEY BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES: PROFILES

ABBVIE

  • Table 3-1: AbbVie Corporate Summary
  • Company Overview
    • Table 3-2: Selected AbbVie Biopharmaceutical Products
    • Table 3-3: Selected Biopharmaceuticals in Development
    • Table 3-4: Selected Corporate Developments
  • Company Financials
    • Table 3-5: AbbVie (2015-2017) ($ millions)

AGILENT TECHNOLOGIES INC.

  • Table 3-6: Agilent Corporate Summary
  • Company Overview
    • Figure 3-1: Agilent Regional Breakdown by % (Americas, Europe, Asia Pacific, Rest of World)
  • Company Financials
    • Table 3-7: Agilent (2015-2017) ($ millions)

ALEXION PHARMACEUTICALS INC

  • Table 3-8: Alexion Corporate Summary
  • Company Overview
    • Figure 3-2: Alexion Regional Breakdown by % (US, Europe, Asia Pacific, Rest of World)
    • Table 3-9: Selected Alexion Biopharmaceutical Products
    • Table 3-10: Selected Alexion Biopharmaceuticals in Development
  • Company Financials
    • Table 3.11: Alexion (2015-2017) ($ millions)

ALLERGAN PLC

  • Table 3-12: Allergan Corporate Summary
  • Company Overview
    • Table 3-13: Selected Corporate Developments
  • Company Financials
    • Table 3-14: Allergan (2015-2017) ($ millions)

AMBRY GENETICS

  • Table 3-15: Ambry Genetics Corporate Summary
  • Company Overview

AMGEN, INC

  • Table 3-16: Amgen Corporate Summary
  • Company Overview
    • Figure 3-3: Amgen Regional Breakdown by % (US, Rest of World)
    • Table 3-17: Selected Biopharmaceutical Products
    • Table 3-18: Selected Amgen Biopharmaceuticals in Development
    • Table 3-19: Selected Corporate Developments
  • Company Financials
    • Table 3-20: Amgen (2015-2017) ($ millions)

ASTRAZENECA PLC

  • Table 3-21: AstraZeneca Corporate Summary
  • Company Overview
    • Figure 3-4: AstraZeneca Regional Breakdown by % (US, Europe, Japan, Rest of World)
    • Table 3-22: Selected Biopharmaceuticals Products
    • Table 3-23: Selected Biopharmaceuticals in Development
    • Table 3-24: Selected Corporate Developments
  • Company Financials
    • Table 3-25: AstraZeneca (2015-2017) ($ millions)

BAYER AG

  • Table 3-26: Bayer AG Corporate Summary
  • Company Overview
    • Figure 3-5: Bayer Regional Breakdown by % (North America, EMEA, Asia Pacific, Latin America, Rest of World)
    • Table 3-27: Selected Bayer AG Biopharmaceutical Products
    • Table 3-28: Selected Biopharmaceuticals in Development
    • Table 3-29: Selected Corporate Developments
  • Company Financials
    • Table 3-30: Bayer (2015-2017) ($ millions)

BERRY GENOMICS CO LTD.

  • Table 3-31: Berry Genomics Corporate Summary
  • Company Overview

BIOGEN

  • Table 3-32: Biogen Corporate Summary
  • Company Overview
    • Figure 3-6: Biogen Regional Breakdown by % (US, Rest of World)
    • Table 3-33: Selected Biopharmaceutical Products
    • Table 3-34: Selected Biopharmaceuticals in Development
    • Table 3-35: Selected Corporate Developments
  • Company Financials
    • Table 3-36: Biogen (2015-2017) ($ millions)

BIOMARIN PHARMACEUTICAL INC

  • Table 3-37: BioMarin Pharmaceutical Corporate Summary
  • Company Overview
    • Figure 3-7: BioMarin Regional Breakdown by % (US, Europe, Latin America, Rest of World)
    • Table 3-38: Selected Biopharmaceuticals Products
    • Table 3-39: Selected Biopharmaceuticals in Development
  • Company Financials
    • Table 3-40: BioMarin (2014-2017) ($ millions)

BRISTOL MYERS SQUIBB

  • Table 3-41: Bristol Myers Squibb Corporate Summary
  • Company Overview
    • Figure 3-8: BMS Regional Breakdown by % (US, Europe, Japan, Rest of World)
    • Table 3-42: Selected Biopharmaceutical Products
    • Table 3-43: Selected Biopharmaceuticals in Development
    • Table 3-44: Selected Corporate Developments
  • Company Financials
    • Table 3-45: BMS (2015-2017) ($ millions)

CELGENE

  • Table 3-46: Celgene Corporate Summary
  • Company Overview
    • Figure 3-9: Celgene Regional Breakdown by % (US, Europe, Rest of World)
    • Table 3-47: Selected Biopharmaceutical Products
    • Table 3-48: Selected Biopharmaceuticals in Development
    • Table 3-49: Selected Corporate Developments
  • Company Financials
    • Table 3-50: Celgene (2015-2017) ($ millions)

CRISPR THERAPEUTICS AG

  • Table 3-51: CRISPR Therapeutics Corporate Summary
  • Company Overview
    • Table 3-52: Selected Corporate Developments
  • Company Financials
    • Table 3-53: CRISPR (2015-2017) ($ thousand)

CSL BEHRING

  • Table 3-54: CSL Behring Corporate Summary
  • Company Overview
    • Table 3-55: Selected Biopharmaceutical Products
    • Table 3-56: Selected Biopharmaceuticals in Development
  • Company Financials
    • Table 3-57: CSL Behring (2015-2017) ($ millions)

DR. REDDY'S LABORATORIES LIMITED

  • Table 3-58: Dr Reddy's Laboratories Corporate Summary
  • Company Overview
  • Company Financials
  • Table 3-59: Dr Reddy's Laboratories (2015-2017) ($ millions)

ELI LILLY & CO

  • Table 3-60: Eli Lilly Corporate Summary
  • Company Overview
    • Figure 3-10: Eli Lilly Regional Breakdown % (US, Rest of World)
    • Table 3-61: Selected Biopharmaceutical Products
    • Table 3-62: Selected Biopharmaceuticals in Development
    • Table 3-63: Selected Corporate Developments
  • Company Financials
    • Table 3-64: Eli Lilly (2015-2017) ($ millions)

ENZO BIOCHEM, INC

  • Table 3-65: Enzo Biochem Corporate Summary
  • Company Overview
  • Company Financials
    • Table 3-66: Enzo Biochem (2014-2017) ($ thousands)

EVOTEC AG

  • Table 3-67: Evotec AG Corporate Summary
  • Company Overview
    • Figure 3-11: Evotec Regional Breakdown by % (Europe, US, Rest of World)
    • Table 3-68: Selected Corporate Developments
  • Company Financials
    • Table 3-69: Evotec (2015-2017) ($ Thousands)

EXELIXIS

  • Table 3-70: Exelixis Corporate Summary
  • Company Overview
    • Figure 3-12: Exelixis Regional Breakdown by % (US, Europe, Japan)
    • Table 3-71: Selected Biopharmaceutical Products
    • Table 3-72: Selected Biopharmaceuticals in Development
    • Table 3-73: Selected Corporate Developments
  • Company Financials
    • Table 3-74: Exelixis (2015-2017) ($ thousands)

GENMAB

  • Table 3-75: Genmab Corporate Summary
  • Company Overview
    • Table 3-76: Selected Biopharmaceutical Products
    • Table 3-77: Selected Biopharmaceuticals in Development
    • Table 3-78: Selected Corporate Developments
  • Company Financials
    • Table 3-79: Genmab (2015-2017) ($ thousands)

GILEAD SCIENCES

  • Table 3-80: Gilead Sciences Corporate Summary
  • Company Overview
    • Figure 3-13: Gilead Sciences Regional Breakdown by % (US, Europe, Japan, Rest of World)
    • Table 3-81: Selected Biopharmaceuticals in Development
    • Table 3-82: Selected Corporate Developments
  • Company Financials
    • Table 3-83: Gilead (2015-2017) ($ millions)

GLAXOSMITHKLINE

  • Table 3-84: GlaxoSmithKline Corporate Summary
  • Company Overview
    • Figure 3-14: GSK Regional Breakdown by % (US, Europe, Rest of World)
    • Table 3-85: Selected Biopharmaceutical Products
    • Table 3-86: Selected Biopharmaceuticals in Development
    • Table 3-87: Selected Corporate Developments
  • Company Financials
    • Table 3-88: GSK (2015-2017) ($ millions)

GRIFOLS INTERNATIONAL S.A.

  • Table 3-89: Grifols International S.A. Corporate Summary
  • Company Overview
    • Figure 3-15: Grifols Regional Breakdown by % (North America, Europe, Rest of World)
    • Table 3-90: Selected Biopharmaceutical Products
    • Table 3-91: Selected Corporate Development
  • Company Financials
    • Table 3-92: Grifols (2015-2017) ($ millions)

GUARDANT HEALTH

  • Table 3-93: Guardant Health Corporate Summary
  • Company Overview

ILLUMINA

  • Table 3-94: Illumina Corporate Summary
  • Company Overview
  • Company Financials
    • Table 3-95: Illumina (2015-2017) ($ millions)

INCYTE CORPORATION

  • Table 3-96: Incyte Corporate Summary
  • Company Overview
    • Table 3-97: Selected Biopharmaceutical Products
    • Table 3-98: Selected Biopharmaceuticals in Development
    • Table 3-99: Selected Corporate Development
  • Company Financials
    • Table 3-100: Incyte (2015-2017) ($ millions)

JOHNSON & JOHNSON

  • Table 3-101: Johnson & Johnson Corporate Summary
  • Company Overview
    • Figure 3-16: J&J Regional Breakdown by % (US, Europe, Asia Pacific/Africa, Rest of World)
    • Table 3-102: Selected Biopharmaceutical Products
    • Table 3-103: Selected Biopharmaceuticals in Development
    • Table 3-104: Selected Corporate Developments
  • Company Financials
    • Table 3-105: J&J (2015-2017) ($ millions)

MERCK & CO, INC.

  • Table 3-106: Merck Corporate Summary
  • Company Overview
    • Figure 3-17: Merck Regional Breakdown by % (US, EMEA, Japan, Asia Pacific, Latin America, Rest of World)
    • Table 3-107: Selected Biopharmaceutical Products
    • Table 3-108: Selected Biopharmaceuticals in Development
    • Table 3-109: Selected Corporate Developments
  • Company Financials
    • Table 3-110: Merck (2015-2017) ($ millions)

MYLAN

  • Table 3-111: Mylan Corporate Summary
  • Company Overview
    • Figure 3-18: Mylan Regional Breakdown by % (North America, Europe, Rest of World)
  • Company Financials
    • Table 3-112: Mylan (2015-2017) ($ millions)

MYRIAD GENETICS

  • Table 3-113: Myriad Genetics Corporate Summary
  • Company Overview
    • Table 3-114: Selected Corporate Developments
  • Company Financials
    • Table 3-115: Myriad (2015-2017) ($ millions)

NOVARTIS INTERNATIONAL AG

  • Table 3-116: Novartis Corporate Summary
  • Company Overview
    • Figure 3-19: Novartis Regional Breakdown by % (US, Europe, Asia Pacific, Rest of World)
    • Table 3-117: Selected Biopharmaceutical Products
    • Table 3-118: Selected Biopharmaceuticals in Development
    • Table 3-119: Selected Corporate Developments
  • Company Financials
    • Table 3-120: Novartis (2015-2017) ($ millions)

NOVO NORDISK A/S

  • Table 3-121: Novo Nordisk Corporate Summary
  • Company Overview
    • Figure 3-20: Novo Nordisk Regional Breakdown by % (North America, Europe, Japan, South Korea, China, Rest of World)
    • Table 3-122: Selected Biopharmaceutical Products
    • Table 3-123: Selected Biopharmaceuticals in Development
  • Company Financials
    • Table 3-124: Novo Nordisk (2015-2017) ($ millions)
  • ORGANOGENESIS
    • Table 3-125: Organogenesis Corporate Summary
  • Company Overview

OXFORD NANOPORE TECHNOLOGIES

  • Table 3-126: Oxford Nanopore Technologies Corporate Summary
  • Company Overview

PERKIN ELMER, INC

  • Table 3-127: Perkin Elmer Corporate Summary
  • Company Overview
    • Table 3-128: Selected Corporate Developments
  • Company Financials
    • Table 3-129: PerkinElmer (2015-2017) ($ millions)

PFIZER

  • Table 3-130: Pfizer Corporate Summary
  • Company Overview
    • Figure 3-21: Pfizer Regional Breakdown by % (US, Japan, Rest of World)
    • Table 3-131: Selected Biopharmaceutical Products
    • Table 3-132: Selected Biopharmaceuticals in Development
    • Table 3-133: Selected Corporate Developments
  • Company Financials
    • Table 3-134: Pfizer (2015-2017) ($ millions)

PRECISION BIOSCIENCES INC.

  • Table 3-135: Precision BioSciences Corporate Summary
  • Company Overview

QIAGEN N.V.

  • Table 3-136: QIAGEN Corporate Summary
  • Company Overview
    • Figure 3-22: QIAGEN Regional Breakdown by % (Americas, EMEA, Asia Pacific & Rest of World)
    • Table 3-137: Selected Corporate Developments
  • Company Financials
    • Table 3-138: QIAGEN (2015-2017) ($ millions)

REGENERON PHARMACEUTICALS

  • Table 3-139: Regeneron Corporate Summary
  • Company Overview
    • Table 3-140: Selected Biopharmaceutical Products
    • Table 3-141: Selected Biopharmaceuticals in Development
    • Table 3-142: Selected Corporate Developments
  • Company Financials
    • Table 3-143: Regeneron (2015-2017) ($ millions)

ROCHE LTD.

  • Table 3-144: Roche Corporate Summary
  • Company Overview
    • Figure 3-23: Roche Regional Breakdown by % (North America, Europe, Japan, Asia Pacific, Rest of World)
    • Table 3-145: Selected Biopharmaceutical Products
    • Table 3-146: Selected Biopharmaceuticals in Development
  • Company Financials
    • Table 3-147: Roche (2015-2017) ($ millions)

SANOFI

  • Table 3-148: Sanofi Corporate Summary
  • Company Overview
    • Figure 3-24: Sanofi Regional Breakdown by % (US, Europe, Rest of World)
    • Table 3-149: Selected Biopharmaceutical Products
    • Table 3-150: Selected Biopharmaceuticals in Development
    • Table 3-151: Selected Corporate Developments
  • Company Financials
    • Table 3-152: Sanofi (2015-2017) ($ millions)

SEATTLE GENETICS, INC.

  • Table 3-153: Seattle Genetics Corporate Summary
  • Company Overview
    • Table 3-154: Selected Biopharmaceuticals in Development
    • Table 3-155: Selected Corporate Developments
  • Company Financials
    • Table 3-156: Seattle Genetics (2015-2017) ($ millions)

SHIRE

  • Table 3-157: Shire Corporate Summary
  • Company Overview
    • Table 3-158: Selected Biopharmaceutical Products
    • Table 3-159: Selected Biopharmaceuticals in Development
    • Table 3-160: Selected Corporate Development
  • Company Financials
    • Table 3-161: Shire (2015-2017) ($ millions)

TAKEDA

  • Table 3-162: Takeda Corporate Summary
  • Company Overview
    • Figure 3-25: Takeda Regional Breakdown by % (US, Europe, Japan, Rest of World)
    • Table 3-163: Selected Biopharmaceutical Products
    • Table 3-164: Selected Biopharmaceuticals in Development
    • Table 3-165: Selected Corporate Developments
  • Company Financials
    • Table 3-166: Takeda (2015-2017) ($ millions)

TEVA PHARMACEUTICAL INDUSTRIES, LTD.

  • Table 3-167: Teva Corporate Summary
  • Company Overview
    • Figure 3-26: Teva Regional Breakdown by % (US, Europe, Rest of World)
    • Table 3-168: Selected Biopharmaceutical Products
    • Table 3-169: Selected Biopharmaceuticals in Development
    • Table 3-170: Selected Corporate Developments
  • Company Financials
    • Table 3-171: Teva (2015-2017) ($ millions)

THERMO FISHER SCIENTIFIC, INC

  • Table 3-172: Thermo Fisher Scientific Corporate Summary
  • Company Overview
    • Table 3-173: Selected Corporate Developments
  • Company Financials
    • Table 3-174: Thermo Fisher Scientific (2015-2017) ($ millions)

UCB S.A.

  • Table 3-175: UCB Corporate Summary
  • Company Overview
    • Table 3-176: Selected Biopharmaceuticals in Development
    • Table 3-177: Selected Corporate Developments
  • Company Financials
    • Table 3-178: UCB (2015-2017) ($ millions)

UNITED THERAPEUTICS CORPORATION

  • Table 3-179: United Therapeutics Corporate Summary
  • Company Overview
    • Table 3-180: Selected Biopharmaceuticals in Development
  • Company Financials
    • Table 3-181: United Therapeutics (2015-2017) ($ millions)

WATERS CORPORATION

  • Table 3-182: Waters Corporate Summary
  • Company Overview
    • Figure 3-27: Waters Regional Breakdown by % (US, Europe, Asia, Rest of World)
  • Company Financials
    • Table 3-183: Waters (2015-2017) ($ millions)
Back to Top